Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05173103
Other study ID # HERMIONE 13
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 24, 2021
Est. completion date January 30, 2024

Study information

Verified date December 2023
Source University of Milano Bicocca
Contact Marina Cazzaniga, MD
Phone +39 039 2333683
Email marina.cazzaniga@asst-monza.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Description of the choices for second line treatment, in the normal clinical practice of the centers adhering to the Hermione Network, in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy.


Description:

Multicenter retrospective observational study, describing therapeutic choices as second-line treatment in patients with HR + / HER2- advanced breast cancer in a real world setting, in centers adhering to the Hermione Network. The study involves the analysis of patients with HR + / HER2- advanced breast cancer treated in second line after initial treatment failure with aromatase inhibitor or Fulvestrant + CDK4 / 6i (Palbociclib, Ribociclib or Abemaciclib). Data will be collected from 150 patients with at least one radiological re-evaluation of disease during 2nd-line treatment from 01 January 2016 until 31 December 2020. List of collected information: Patients' characteristics (gender, age at diagnosis, menopausal state); Disease definition at diagnosis (stage, tumour histology, hormonal status); Surgery (date of surgery, type of surgical approach); Neo-adjuvant treatment; Adjuvant treatment; Date of first relapse (and time since the end of adjuvant therapy); Locations of metastases, Biopsy of metastases, Hormonal receptor status; First-line treatment, hormonal therapy, Best response, Cause of treatment end; Second-line treatment, Best response (radiological re-evaluation), Toxicity, Cause of treatment end. Demographics, baseline characteristics (including tumor characteristics) and treatment information will be summarized descriptively. The categorical variables will be presented in the form of frequencies and percentages, while the continuous variables will be presented by mean, standard deviation and minimum and maximum values. A logistic model will be used for the analysis of clinical benefit (categorical variable), while for the analysis of time-to-event indicators a proportional hazard model will be used. For both analyses, the optimal model will be chosen with the method of "backward" selection. A threshold value of 5% will be used to include predictive variables in the model. The estimates derived by the final models will be evaluated using a penalized model for the evaluation of maximal probability, according to the Firth approach.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date January 30, 2024
Est. primary completion date January 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - age> 18 years - female sex - Performance Status (ECOG) 0-2; - hormonal-receptor positive breast cancer (Estrogen and / or Progesterone positive), HER2 negative, with evidence of stage IV / locally advanced inoperable disease - Radiologically documented progression in 1st line treatment with Hormonal Therapy (Aromatase inhibitor / Fulvestrant) + CDK4-6i (Palbociclib / Ribociclib / Abemaciclib) - Execution of at least one subsequent therapeutic line chosen by the clinician, with at least one radiological re-evaluation during this treatment by 31 December 2020. - Radiologically measurable or evaluable lesions - Written informed consent Exclusion Criteria: - age <18 years - previous neoplastic pathology, within 5 years of the last active treatment - Previous chemotherapy treatments, with biological or endocrine therapies for advanced disease, different from first-line therapy with OT + CDK4 / 6i

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Clinica Oncologica Aou Ospedali Riuniti Ancona
Italy Ospedale Cardinal Massaia Asti Asti
Italy Ospedale San Martino Belluno
Italy OSPEDALE Sacro Cuore di Gesù - Fatebenefratelli Benevento
Italy Spedali Civili Brescia Brescia
Italy Ospedale Sant'Anna, San Fermo della Battaglia Como
Italy ASST Cremona - Area Donna Cremona
Italy ASST VALLE OLONA - Presidio Gallarate - SC Oncologia Gallarate
Italy A.S.S.T. Ovest Milanese Legnano
Italy Ospedale Civile di Livorno, Azienda USL Toscana Nord Ovest Livorno
Italy ISTITUTO ROMAGNOLO per la cura e lo studio dei tumori (IRST-IRCCS) Meldola
Italy ASST Fatebenefratelli Sacco Milano
Italy Policlinico di Milano Ospedale Maggiore, Fondazione IRCCS Ca' Granda Milano
Italy Ospedale San Gerardo Monza
Italy UO Aziendale Olbia Olbia
Italy Ospedale La Maddalena Palermo
Italy ICS Maugeri Spa-SB PAVIA Pavia
Italy U.O.C Oncologia Ospedale "G Da Saliceto" Piacenza
Italy UO Oncologia Medica I Azienda Ospedaliero Universitaria Pisana Pisa
Italy Azienda USL - Arcispedale S. Maria Nuova IRCCS Reggio Emilia
Italy A.S.S.T. Rhodense Ospedale Di Circolo Rho Rho
Italy Oncologia Ospedale di Rimini Rimini
Italy IRCCS Istituto Nazionale Tumori - IFO Regina Elena, Oncologia Medica B Roma
Italy Policlinico Gemelli Roma
Italy AOU città della scienza e della salute SCDO4 Torino
Italy AOU città della scienza e della salute SCDU1 Torino
Italy Oncologia Trento Trento
Italy PIA FONDAZIONE Cardinale PANICO Tricase - Lecce Tricase
Italy ASST SETTELAGHI - Oncologia Varese Varese

Sponsors (1)

Lead Sponsor Collaborator
University of Milano Bicocca

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Description of the choices for second line treatment in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy. Description of the choices for second line treatment, in the normal clinical practice of the centers adhering to the Hermione Network, in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy. Entire study duration, approximately 12 months
Secondary progression-free survival time from the start of treatment to evidence of disease progression or death from date of treatment beginning until the date of first documented progression or date of death from any cause, assessed up to 72 months
Secondary response rate radiological response rate according to RECIST criteria, classified as CR (Complete Response), PR (Partial Response), SD (Stable Disease), PD (Progressive Disease) Entire study duration, approximately 12 months
Secondary Survival Post Progression survival evaluated from from date of treatment beginning until the date of first documented progression or date of death from any cause from date of treatment beginning until the date of first documented progression or date of death from any cause, assessed up to 72 months
Secondary progression by location (visceral versus non-visceral). time from the date second-line treatment beginning to the date of disease progression or death from any cause, stratified according to visceral versus non-visceral diseaes from date of treatment beginning until the date of first documented progression or date of death from any cause, assessed up to 72 months
Secondary Drug toxicities Evaluation of drug related toxicities listed according to the different therapeutic options Entire study duration, approximately 12 months
Secondary Physician's reasons for treatment choice in real world experience Evaluation of the physician's reasons for treatment choice of the second-line therapy after progression to CDK4 / 6i associated with hormonal therapy Entire study duration, approximately 12 months
Secondary Predictive factors of response Evaluation of predictive factors of response through the comparison of four variables according to AIC e R2 criteria Entire study duration, approximately 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04653740 - Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer N/A
Completed NCT02091960 - A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer Phase 2
Recruiting NCT05156619 - Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT00754325 - Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor Phase 2
Recruiting NCT04953377 - PFMT Educational Intervention for Patients With Advancer Breast Cancer N/A
Completed NCT03240224 - Bioinformation Therapy for Breast Cancer Phase 2/Phase 3
Recruiting NCT06193525 - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test Phase 2
Completed NCT03312738 - A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor Phase 2
Active, not recruiting NCT05063786 - Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) Phase 3
Recruiting NCT05655598 - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Phase 1
Active, not recruiting NCT02499146 - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer Phase 1
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Recruiting NCT04456855 - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Completed NCT04408118 - First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Completed NCT03205761 - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer Phase 2
Withdrawn NCT04316169 - Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer Phase 1
Completed NCT00546104 - Phase II Dasatinib Study in Advanced Breast Cancer Phase 2
Completed NCT00387907 - Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer Phase 2